Top Tech Companies (2,061)
Don't see your company?
Create a company profile
MediSpend, a global technology company providing best-in-class solutions for the life sciences industry, is the compliance system of record for some of the world’s largest pharmaceutical, medical device, dental and emerging biotech companies around the world. The MediSpend Global Compliance Suite represents the industry’s first global SaaS solution purpose-built to manage the end-to-end process of HCP/O engagement through transparency reporting, which includes software that facilitates external grant requests. MediSpend solutions are designed to empower life sciences companies to grow their business compliantly. MediSpend is headquartered in Portsmouth, N.H., with offices in Minnesota, New York and Pennsylvania. Visit MediSpend online at www.medispend.com.
Recros Medica is a medical device company developing technologies to treat skin laxity and focal aesthetic contour deformities.
Oscine Therapeutics is a new biotechnology company based on discoveries made and developed at the University of Rochester Medical Center
TriMetis is a preclinical services company that provides biospecimen procurement and specialty laboratory and consultation services.
Lumena Pharmaceuticals develops oral therapeutics for rare liver diseases to improve liver function and relieve disease symptoms.
BHS Biotechnology is a newly formed company, wholly owned by BioHybrid Solutions Holdings, Inc. (BHSH). All BHSH companies are endeavoring under the BioHybrid Solutions (BHS) banner. BHS’s vision is to deliver safe and effective biologic drugs to patients everywhere. Our mission is to harness science for the precise design and development of breakthrough biologic medicines. Our systematic in silico and in vitro process exerts ImmunoControl™ through our EpitopeSilencing™ process, improving pharmacokinetics and increasing the half-life of NanoArmored™ biologic therapeutics while maintaining activity. In addition, the ImmunoControlTM platform can be used for EpitopeTargeting™ and EpitopeAccentuation™ allowing for the discovery of new drugs against secondary, silent epitopes. Visit us at www.biohybridsolutions.com to learn more.
Arytha Biosciences is a nanotechnology-driven and research-focused biotech company.
Invenra is focused on developing the next generation of best-in-class biologics, with an emphasis on multispecific antibodies and their derivatives. Invenra's proprietary technologies combine our highly developable B-Body™ bispecific platform with high throughput functional screening, enabling the optimization of unprecedented numbers of bispecific antibodies in phenotypic assays. Invenra has a pipeline of immuno-oncology bispecific antibodies that are currently in preclinical studies.
Brain Neurotherapy Bio focuses on the clinical translation and development of neurotrophic factor gene therapy.
Texcell-North America, Inc. is a global contract research organization based in the Maryland/Virginia biotech corridor specializing in custom cell culture, virus propagation, virus concentration, viral clearance services, and viral safety testing in support of biopharmaceutical applications submitted to the FDA and other regulatory authorities. Since 2002, our team has cultivated an ever-increasing range of experience performing viral clearance studies for a wide variety of purification steps including chromatography, filtration, and inactivation methods, as well as evaluations of column age and sanitization, or cleaning efficacy. We offer our clients a personalized and tailored approach to study design with the advantage of an extensive historical viral clearance database of over 9,000 studies performed by our global organization. Through partnerships with other Texcell facilities around the world, we have expanded our services portfolio to include cGMP cell bank production, cell bank characterization and GMP compliant animal studies. We are proud to support research that continues to improve global quality of life. Let us be an extension of your laboratory. To find out more about our viral safety, viral clearance, cell culture and viral propagation capabilities, visit our website or contact us at the link below: http://www.texcell.com/contact-us/
Tarsa Therapeutics develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.
Arcadia Biosciences is an agricultural technology company developing products that benefit the environment and human health.
BioGenix grew out of the recognition of the important potential of regenerative medicine in giving hope to patients who suffer from past injuries, chronic conditions, or degenerative disease. Out of this potential grew the demand for safe, reliable, ethically sound regenerative products -- and BioGenix was up to the task. Working directly with hospitals participating in umbilical cord tissue donation programs and partnering with a trusted, sterile FDA registered lab, we turned concept into reality, bringing BioGenix regenerative products to physicians across many medical specialties domestically and around the world. By choosing to use only umbilical cord derived regenerative medicine products, we harness the medical advantages of growth-factor rich tissue while circumventing invasive procedures and providing a product that aligns with our ethics.
Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Gentueri works with laboratories to improve the quality of results and laboratory efficiency.
Meditrina Pharmaceuticals, a clinical-stage pharmaceutical company, develops innovative therapies that treat women's reproductive disorders.
4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations. We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: - Dare to Cure - Break Boundaries - Beyond Yourself - Prepare & Executive Relentlessly
Tioma Therapeutics is a venture-stage biopharmaceutical company.
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the company's partners make progress developing and commercializing their products being developed with ENHANZE®. We are a diverse team, who are committed to bringing therapies and results to patients. It's not enough to be qualified and experienced at what you do, we are looking for people who believe in our mission and match our values. We are building a company where people can pursue their career goals in a supportive and collaborative team environment. Visit www.halozyme.com/careers for more details. We are Halozyme.
TRACON Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies for cancer and macular degeneration.
